IL6 and COVID-19: Dexamethasone alone or in combination with IL-6 inhibitors tocilizumab or anakinra reduced levels of markers associated with cytokine storm including CRP, and improved survival.24 Thus, IL-6 is an early marker for severe COVID-19 that is also an important target for therapy.